Analysts Offer Predictions for Innoviva FY2027 Earnings

Innoviva, Inc. (NASDAQ:INVA) – Research analysts at HC Wainwright issued their FY2027 earnings per share estimates for shares of Innoviva in a report issued on Monday, March 2nd. HC Wainwright analyst R. Selvaraju forecasts that the biotechnology company will earn $2.50 per share for the year. HC Wainwright currently has a “Buy” rating and a $46.00 target price on the stock. The consensus estimate for Innoviva’s current full-year earnings is $0.33 per share.

Innoviva (NASDAQ:INVA) last released its quarterly earnings data on Wednesday, February 25th. The biotechnology company reported $1.94 earnings per share for the quarter, topping the consensus estimate of $0.34 by $1.60. Innoviva had a net margin of 65.92% and a return on equity of 37.63%. The business had revenue of $114.61 million for the quarter, compared to analyst estimates of $102.62 million.

A number of other analysts have also recently commented on the stock. BTIG Research restated a “buy” rating and issued a $35.00 price objective on shares of Innoviva in a research report on Thursday, February 26th. Weiss Ratings restated a “buy (b)” rating on shares of Innoviva in a report on Monday, December 29th. Zacks Research lowered Innoviva from a “strong-buy” rating to a “hold” rating in a research report on Thursday, November 6th. Finally, Cantor Fitzgerald boosted their price objective on Innoviva from $29.00 to $31.00 and gave the company an “overweight” rating in a research report on Thursday, November 6th. Six research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $38.17.

Innoviva Trading Up 1.9%

INVA opened at $22.73 on Thursday. The firm’s fifty day moving average is $21.04 and its two-hundred day moving average is $20.12. The firm has a market cap of $1.70 billion, a PE ratio of 7.45 and a beta of 0.42. Innoviva has a twelve month low of $16.52 and a twelve month high of $25.15. The company has a debt-to-equity ratio of 0.22, a quick ratio of 13.85 and a current ratio of 14.64.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the company. Invesco Ltd. lifted its stake in Innoviva by 8.8% in the 4th quarter. Invesco Ltd. now owns 832,635 shares of the biotechnology company’s stock valued at $16,644,000 after acquiring an additional 67,069 shares in the last quarter. Vident Advisory LLC acquired a new stake in shares of Innoviva in the fourth quarter valued at approximately $565,000. NewEdge Advisors LLC raised its holdings in shares of Innoviva by 79.2% in the fourth quarter. NewEdge Advisors LLC now owns 35,984 shares of the biotechnology company’s stock valued at $719,000 after purchasing an additional 15,899 shares during the last quarter. Empowered Funds LLC bought a new stake in shares of Innoviva in the fourth quarter worth $1,492,000. Finally, Uniplan Investment Counsel Inc. boosted its holdings in Innoviva by 9.5% during the fourth quarter. Uniplan Investment Counsel Inc. now owns 209,733 shares of the biotechnology company’s stock worth $4,193,000 after purchasing an additional 18,263 shares during the last quarter. 99.12% of the stock is currently owned by institutional investors.

Innoviva News Roundup

Here are the key news stories impacting Innoviva this week:

• Positive Sentiment: HC Wainwright reiterated a “Buy” rating on INVA and set a $46 price target, signaling strong upside potential relative to current market levels. This bullish stance can support buying interest and investor confidence. MarketBeat Innoviva Coverage
• Neutral Sentiment: HC Wainwright issued a set of multi‑quarter forecasts for FY2026–FY2027 (e.g., FY2026 $1.96 EPS; Q1–Q4 2027 progressive quarterly EPS projections), providing a roadmap for expected earnings recovery beyond the near term. Investors can use these as a baseline to compare upcoming reports. MarketBeat Innoviva Coverage
• Neutral Sentiment: Theravance Biopharma announced a Phase 3 trial failure and program halt; while this has driven heavy moves in Theravance shares, any impact on Innoviva depends on the specific royalty/exposure relationships (not explicitly detailed in the updates). Monitor disclosure of any direct royalty link or material revenue dependency. Theravance Plummets As Phase 3 Study Falls Short Theravance Restructures After Trial Failure
• Negative Sentiment: HC Wainwright cut several near‑term EPS estimates: Q1–Q4 2026 and specific quarter forecasts were reduced (examples: Q1 2026 to $0.42 from $0.45; Q2 2026 to $0.51 from $0.56; Q3 2026 to $0.48 from $0.57; Q4 2026 to $0.55 from $0.66), and FY2026 was trimmed to $1.96 from $2.23. These downward revisions may pressure sentiment and short‑term stock performance until results validate the updated cadence. MarketBeat Innoviva Coverage

Innoviva Company Profile

Innoviva, Inc, incorporated in Delaware and headquartered in San Francisco, California, is a royalty-focused life sciences company. It acquires, manages and monetizes royalty and license interests in biopharmaceutical products, with a primary emphasis on inhaled respiratory therapies. Innoviva’s portfolio is anchored by royalties on therapies originally developed by its former affiliate, now marketed by GlaxoSmithKline, including several long-acting inhaled products approved for chronic obstructive pulmonary disease (COPD) and asthma.

The company was established through a spin‐out transaction in 2014, separating the royalty assets from a research‐based biopharmaceutical enterprise to create a specialized investment vehicle.